Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00, implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering. The company plans to list on the Nasdaq Global Select Market under the ticker ALMR, with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel.
Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection. At the core of the platform is its proprietary NULISA technology, designed to overcome longstanding limitations in proteomics by delivering ultra-high sensitivity, high specificity, and multiplexing capabilities within a fully automated workflow. The company positions this as a foundational shift from traditional protein analysis toward scalable, high-resolution biomarker detection across research, translational medicine, and ultimately clinical diagnostics.
The platform is built around an integrated ecosystem of instruments, consumables, and software, anchored by the ARGO HT System, which was commercially launched in early 2024. Adoption has ramped quickly, with more than 300 customers across 25 countries and an installed base exceeding 100 instruments, generating over $400,000 in annual consumable pull-through per instrument. This model reflects a classic life sciences tools dynamic, where instrument placements drive a growing base of recurring, high-margin consumables revenue.
Alamar’s financial profile reinforces that transition from early commercialization to scale. Revenue increased from $25.1 million in 2024 to $74.2 million in 2025, a roughly 3x step-up, driven by accelerating instrument adoption and rising consumables pull-through. That mix shift is showing up in the model, with gross margin expanding from 34.2% to 56.2%, signaling improving unit economics as the installed base builds. Losses are narrowing at the same time, with operating loss improving from $49.6 million to $31.3 million and net loss declining from $47.1 million to $29.8 million, even as the company continues to invest in R&D and commercial infrastructure. The result is a business beginning to show early operating leverage, with a clearer path toward a recurring revenue-driven model.
The broader opportunity is substantial. The company estimates its addressable market across proteomics research and immunoassay diagnostics at nearly $50 billion today, with expectations to grow toward $80 billion over the next decade. Within that, advanced proteomics—where Alamar is focused—represents a fast-growing segment driven by increasing demand for multi-analyte biomarker detection and the shift toward precision medicine and earlier disease diagnostics.
Strategically, Alamar is pursuing a land-and-expand model—first driving adoption in research and translational settings, then extending into clinical diagnostics through both internal development and partnerships. A key milestone ahead is the ARGO HT/DX platform, with plans to pursue FDA authorization around 2027, marking a potential transition from research-use-only applications into regulated clinical markets.
Risk remains centered on execution. The company operates in a competitive and rapidly evolving proteomics landscape and must continue driving adoption, expanding its assay menu, and successfully bridging into clinical diagnostics. That transition introduces both regulatory and validation risk, particularly as the company moves closer to patient-facing applications.
Overall, Alamar enters the public markets positioned at the intersection of life sciences tools and diagnostics, with a differentiated platform, strong early growth, and a model increasingly driven by recurring consumables revenue. The IPO ultimately represents a bet on whether precision proteomics can move from a research tool into a foundational layer of next-generation diagnostics.
Alamar Biosciences will make it’s public market debut on Friday, April 17th, 2026.